SEER - NASDAQ
Seer, Inc.
$1.85
-1.1%Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
At a Glance
Live Snapshotseer
Net Cash Provided by Financing Activities
Last Annual Value
-10.57M
3-Year CAGR
-55%
5-Year CAGR
-1%
10-Year CAGR
-3%
Seer, Inc. Competitors Analysis of Net Cash Provided by Financing Activities
| Company | Net Cash Provided by Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Seer, Inc. NASDAQ:SEER | -10.57M | N/A | N/A | N/A | |
 Foghorn Therapeutics Inc. NASDAQ:FHTX | 1.02M | -16.8% | -46.1% | N/A | |
 Kymera Therapeutics, Inc. NASDAQ:KYMR | 990.71M | 518.3% | 31.7% | N/A | |
 MediciNova, Inc. NASDAQ:MNOV | 244.02K | N/A | -58.9% | -30.0% | |
 C4 Therapeutics, Inc. NASDAQ:CCCC | 126.40M | 40.6% | -5.9% | N/A | |
 AN2 Therapeutics, Inc. NASDAQ:ANTX | 113.00K | -89.0% | -73.0% | N/A | |
 Nkarta, Inc. NASDAQ:NKTX | 141.00K | -41.1% | -34.9% | N/A | |
 Nurix Therapeutics, Inc. NASDAQ:NRIX | 238.64M | 320.2% | 9.2% | N/A | |
 Mineralys Therapeutics, Inc. NASDAQ:MLYS | 591.00M | 42.7% | 90.1% | N/A | |
 Lyell Immunopharma, Inc. NASDAQ:LYEL | 50.41M | 206.9% | -34.0% | N/A | |
 Quantum-Si incorporated NASDAQ:QSI | 95.42M | 762.0% | -28.7% | N/A |
Seer, Inc. Fair Value Envelope
Related Guides
Continue your SEER research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.